Abstract: Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
Type:
Grant
Filed:
October 27, 2017
Date of Patent:
January 4, 2022
Assignee:
TARVEDA THERAPEUTICS, INC.
Inventors:
Rajesh R. Shinde, Rossitza G. Alargova, Patrick Lim Soo, Beata Sweryda-Krawiec, Leila Alland, Christopher Sears
Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Type:
Grant
Filed:
May 12, 2020
Date of Patent:
January 4, 2022
Assignee:
METACRINE, INC.
Inventors:
Nicholas D. Smith, Steven P. Govek, Johnny Y. Nagasawa
Abstract: Disclosed herein are nanoconstructs comprising a nanoparticle, coated with additional agents such as cationic polymers, stabilizers, targeting molecules, labels, oligonucleotides and small molecules. These constructs may be used to deliver compounds to treat solid tumors and to diagnose cancer and other diseases. Further disclosed are methods of making such compounds and use of such compounds to treat or diagnose human disease.
Type:
Grant
Filed:
February 10, 2017
Date of Patent:
December 28, 2021
Assignees:
Oregon Health & Science University, PDX Pharmaceuticals, Inc.
Inventors:
Wassana Yantasee, Worapol Ngamcherdtrakul, Jingga Morry, David Castro, Joe Gray
Abstract: Provided herein are compounds useful for binding to one or more histone deacetylase enzymes (HDACs). The present application further provides radiolabeled compounds useful as a radiotracer for position emission tomography imaging of HDAC. Methods for prepared unlabeled and labeled compounds, diagnostic methods, and methods of treating diseases associated HDAC are also provided.
Type:
Grant
Filed:
April 11, 2018
Date of Patent:
December 28, 2021
Assignee:
The General Hospital Corporation
Inventors:
Jacob Hooker, Changning Wang, Martin Georg Strebl-Bantillo
Abstract: The invention provides a method of preparing a 89Zr-oxine complex of the formula The invention also provides a method of labeling a cell with the 89Zr-oxine complex and a method for detecting a biological cell in a subject comprising administering the 89Zr-oxine complex to the subject.
Type:
Grant
Filed:
December 20, 2019
Date of Patent:
December 7, 2021
Assignee:
The United States of Americans, as represented by the Secretary, Department of Health and Human Services
Inventors:
Noriko Sato, Haitao Wu, Gary L. Griffiths, Peter L. Choyke
Abstract: The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.
Type:
Grant
Filed:
May 4, 2018
Date of Patent:
December 7, 2021
Assignee:
Centre for Probe Development and Commercialization
Inventors:
Eric Steven Burak, Stuart James Mahoney, Ryan Wayne Simms, John Fitzmaurice Valliant, Alla Darwish
Abstract: Molecular probes for detecting and imaging pancreatic cancer are disclosed. The probes are modified benzoxanthene fluorophores, which are selectively taken up by pancreatic cancer cells, such as pancreatic ductal adenocarcinoma cells. Embodiments of the disclosed probes are useful for pancreatic cancer detection, therapeutic monitoring, and/or image-guided surgery.
Type:
Grant
Filed:
May 23, 2017
Date of Patent:
December 7, 2021
Assignee:
Portland State University
Inventors:
Robert M Strongin, Martha Sibrian-Vazquez, Lei Wang, Jorge O. Escobedo Cordova, Mark A. Lowry
Abstract: The invention relates to a process for the preparation of a diagnostic X-ray composition. The composition comprises a non-ionic X-ray contrast agent in a pharmaceutically acceptable carrier. More particularly, the invention relates to a process for secondary production of X-ray compositions comprising X-ray contrast agents with a high dissolution temperature. When using the process of the invention, precipitation is avoided and degradation of the contrast agent is reduced. The process of the invention includes heat treatment of iodinated X-ray contrast agents at low pH.
Abstract: The present invention relates to contrast agent enhanced medical ultrasound imaging. In particular, the contrast agents provided are useful for cell imaging and cell therapy, as well as in vivo targeting, drug delivery and perfusion or vascular imaging applications. More specifically, it provides a particle comprising a fluorinated organic compound and a metal. Such particles may be advantageously employed in qualitative or quantitative imaging such as acoustic imaging including photoacoustic and ultrasound imaging, MRI imaging, such as 19F imaging, 1H imaging including T1 and T2 weighted imaging, SPECT, PET, scintigraphy, fluorescence imaging and optical coherence imaging and tomographic applications. This may then be employed in cell labeling, microscopy, histology or for imaging vasculature or perfusion in vivo and in vitro.
Type:
Grant
Filed:
September 14, 2013
Date of Patent:
November 30, 2021
Assignee:
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Inventors:
Carl Gustav Figdor, Ingrid Jolanda Monique De Vries, Mangala Srinivas, Luis Javier Cruz Ricondo, Christoffel Leendert De Korte
Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that chelates a radioactive metal isotope are disclosed herein. The alkylphophocholine analogs, which can be used to treat or detect solid tumors, have the formula: R1 includes a chelating agent that is chelated to a metal atom, wherein the metal atom is a positron or single photon emitting metal isotope with a half life of greater than or equal to 4 hours, or an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2.
Abstract: Systems and methods including a material that emits high energy beta particles to destroy cancer cells contained in cancerous tumor or tissue. Electronic neutron generators produce neutrons with energies that have a high probability to interact with the material yttrium-89 to produce yttrium-90. Yttrium-90 emits beta radiation with a maximum energy of about 2.25 MeV and a half-life of about 64 hours, which decays to stable zirconium. Stable yttrium-89 can be directly placed in or around cancerous tissue and irradiated with neutrons in the 0.1-15 KeV energy range to produce significant amounts of yttrium-90. The beta radiation emitted by yttrium-90 will primarily destroy the more radiation sensitive cancer cells within the range of the beta particles. The resulting zirconium isotope is not radioactive such that no further radiation is released. A low probability gamma is also created that will assist in cancer cell destruction.
Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.
Type:
Grant
Filed:
November 1, 2019
Date of Patent:
November 23, 2021
Assignee:
Wyeth LLC
Inventors:
Eric Joel Benjamin, Wendy Ann Dulin, Yanning Lin, Kai Zhuang
Abstract: The present invention describes a compound of formula (I) which can be used in the diagnosis, treatment or prevention of neurotensin receptor-related conditions such as tumors and hematological malignancies.
Abstract: The present invention provides dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and compositions thereof. The chemiluminescence probes disclosed are useful for both diagnostics and in vivo imaging.
Type:
Grant
Filed:
April 16, 2020
Date of Patent:
November 23, 2021
Assignee:
RAMOT AT TEL-AVIV UNIVERSITY LTD.
Inventors:
Doron Shabat, Ronit Satchi-Fainaro, Nir Hananya, Ori Green, Tal Eilon
Abstract: The present invention relates to novel tricarbocyanine-cyclodextrin(s) conjugates useful as markers in the diagnosis of kidney diseases, a diagnostic composition comprising said conjugates, their use and their production.
Abstract: An edible negative contrast agent for CT imaging of the gastrointestinal tract intended for oral intake. The contrast agent is a fluid, aqueous foam displaying a CT density contrast value in the range ?300 to ?800 HU and having a consistency of 7 to 12 cm as measured with Bostwick consistometer. The contrast agent comprises an aqueous continuous liquid phase having a pH of 6.5 to 8.0 and gas bubbles dispersed in the continuous aqueous liquid phase. The aqueous continuous liquid phase comprises a surfactant, the surfactant being a protein, a hydrocolloid acting as foam stabilizer, a buffering agent, and water.
Abstract: The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.
Type:
Grant
Filed:
May 12, 2017
Date of Patent:
November 16, 2021
Assignee:
Lantheus Medical Imaging, Inc.
Inventors:
Ajay Purohit, Pedro Benites, Heike S. Radeke, Joel Lazewatsky, L. Veronica Lee
Abstract: The present invention relates to novel, selective radiolabelled tau ligands which are useful for imaging and quantifying tau aggregates, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue or a subject, in vitro or in vivo, and to precursors of said compounds.
Type:
Grant
Filed:
July 14, 2017
Date of Patent:
November 9, 2021
Assignee:
Janssen Pharmaceutica NV
Inventors:
José Ignacio Andrés-Gil, Guy Maurits R. Bormans, Lieven Denis Herwig Declercq, Katleen Fierens, Joseph Elisabeth Leenaerts, Diederik Willem Elisabeth Moechars, Frederik Jan Rita Rombouts, Hartmuth Kolb, Wei Zhang